The company reported a decline in revenue by 1.3% QoQ (+9.1% YoY) to INR 57,393 Mn in Q4FY23. The drop in revenue was mainly attributable to the decline in India business revenue by 12.8% QoQ (+2.5% YOY) to INR 22,383 Mn (39% of revenue). Although on Ex- COVID basis, the Indian business grew at a healthy rate of 16% owing to increase in demand in flu season. with India business, the company witnessed a robust growth across branded prescription, trade generics and consumer health in FY23.